Standard Biotools (LAB) Liabilities and Shareholders Equity (2010 - 2026)

Standard Biotools (LAB) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $639.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 10.27% year-over-year to $639.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (down 10.79% YoY) and the FY2025 annual result came in at $567.8 million, down 7.28% from the prior year.
• Liabilities and Shareholders Equity climbed to $639.1 million in Q1 2026 per LAB's latest filing, from $567.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $777.7 million in Q1 2024 and bottomed at $271.9 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $539.6 million (2025), against an average of $504.2 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity jumped 109.24%; it then dropped 25.47% in 2025.
• Tracing LAB's Liabilities and Shareholders Equity over 5 years: stood at $390.3 million in 2022, then retreated by 17.23% to $323.1 million in 2023, then surged by 89.54% to $612.3 million in 2024, then slipped by 7.28% to $567.8 million in 2025, then advanced by 12.57% to $639.1 million in 2026.
• Per Business Quant, the three latest LAB Liabilities and Shareholders Equity figures stand at $639.1 million (Q1 2026), $567.8 million (Q4 2025), and $539.6 million (Q3 2025).

Peer Comparison